FDA Panel Bets Big on Six Peptides Amid Safety Debates

An FDA advisory panel voted to recommend approving six of seven peptides previously banned, including BPC-157, TB-500, KPV, MOTS-c, Emideltide, and Semax (Epitalon was rejected), signaling a potential surge in a U.S. peptide industry but drawing scrutiny over safety data and whether it will curb the gray market; final agency approval remains uncertain and could stretch into 2027.